Erosive Esophagitis Management with Proton Pump Inhibitors

Initial Treatment Phase

The American Gastroenterological Association recommends initiating treatment with standard-dose PPI once daily (omeprazole 20 mg, lansoprazole 30 mg, or pantoprazole 40 mg) taken 30-60 minutes before meals for 4-8 weeks for patients with erosive esophagitis 1
PPIs must be taken before meals (not at bedtime) for optimal acid suppression, as recommended by the American College of Gastroenterology 1
Twice-daily dosing is NOT FDA-approved for erosive esophagitis and lacks strong evidence support, according to the European Society of Gastrointestinal Endoscopy 3, 4, 1

The American College of Gastroenterology recommends continuous daily PPI therapy for patients with severe erosive esophagitis (Los Angeles grade C/D) to prevent relapse 6, 5
Maintenance therapy should be titrated to the lowest effective dose based on symptom control, but daily dosing must be maintained, as suggested by the American Gastroenterological Association 5, 1
On-demand or intermittent therapy is NOT recommended for patients with documented erosive esophagitis, as it results in high recurrence rates of erosive disease, according to the European Society of Gastroenterology 5

The severity of erosive esophagitis determines the approach to long-term management, with patients having Los Angeles grade C/D (severe) requiring continuous therapy, as recommended by the American College of Gastroenterology 6
Step-down therapy may be considered after initial healing for patients with Los Angeles grade A/B (mild), but most still require continuous therapy, according to the American Gastroenterological Association 5

The American College of Gastroenterology recommends avoiding on-demand or intermittent therapy for patients with documented erosive esophagitis, as this is only appropriate for non-erosive reflux disease 5
Twice-daily dosing should not be prescribed as initial therapy, as it is not FDA-approved and increases costs without proven benefit for erosive esophagitis, according to the American College of Gastroenterology 1
PPIs should not be discontinued in patients with severe (grade C/D) disease, as these patients require lifelong therapy, as recommended by the European Society of Gastrointestinal Endoscopy 6

All patients on long-term PPI therapy should have their indication clearly documented, as suggested by the American Gastroenterological Association 1
Patients with Barrett's esophagus, severe erosive esophagitis, or esophageal strictures are definitively indicated for long-term use, according to the American College of Gastroenterology 6, 1